Agilis Biotherapeutics Obtains $8,000,000 New Financing Round

  • Feed Type
  • Date
    1/3/2014
  • Company Name
    Agilis Biotherapeutics
  • Mailing Address
    Undisclosed New York, NY 11000
  • Company Description
    Agilis Biotherapeutics, LLC, is a biotechnology company focused on designing and engineering first-in-class DNA-based therapeutics to improve and save the lives of patients affected by life-threatening or fatal rare diseases for which there are no or limited treatment options.
  • Website
    http://www.agilisbio.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $8,000,000
  • Transaction Round
    Undisclosed
  • Proceeds Purposes
    Proceeds from the financing will be used for Agilis’ initial focus on developing a treatment for Friedreich’s ataxia FRDA) in collaboration with Intrexon Corporation (XON), a leader in the field of synthetic biology.
  • M&A Terms
  • Venture Investor
    Undisclosed